Subtopic Deep Dive
Familial Adenomatous Polyposis
Research Guide
What is Familial Adenomatous Polyposis?
Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder caused by germline mutations in the APC tumor suppressor gene, leading to hundreds to thousands of colorectal adenomas and near-certain progression to colorectal cancer without intervention.
FAP accounts for about 1% of colorectal cancers and features early-onset polyposis typically by age 20. APC mutations disrupt β-catenin regulation, activating Wnt signaling and promoting tumorigenesis (Vogelstein et al., 1988; 6722 citations). Over 1000 FAP-associated APC variants have been identified, with genotype-phenotype correlations influencing polyp burden and extracolonic manifestations (Kinzler et al., 1991; 2352 citations).
Why It Matters
FAP research enables predictive genetic testing and prophylactic colectomy, reducing mortality from 100% untreated penetrance to under 1% with screening (Kinzler and Vogelstein, 1996; 4907 citations). Chemoprevention trials like celecoxib demonstrated 28% polyp reduction in FAP patients, informing non-surgical management (Steinbach et al., 2000; 2514 citations). Insights into APC-β-catenin signaling apply to sporadic colorectal cancers, where APC inactivation occurs in 80% of cases (Morin et al., 1997; 3888 citations; He et al., 1998; 4525 citations). These advances guide genetic counseling for 1 in 10,000 individuals at risk.
Key Research Challenges
Genotype-Phenotype Correlation
Mapping specific APC mutations to clinical phenotypes like polyp number, desmoid tumors, and cancer risk remains incomplete due to variant diversity. Kinzler et al. (1991) identified the FAP locus but noted challenges in pinpointing causative alleles. Over 1000 variants complicate predictive modeling (Vogelstein et al., 1988).
Chemoprevention Efficacy
Developing agents to reduce polyp burden without toxicity is limited; celecoxib showed short-term benefits but long-term data are sparse (Steinbach et al., 2000). Trials struggle with small cohorts and surrogate endpoints like polyp count. Optimal dosing and combination therapies need validation.
Extracolonic Manifestation Prediction
Anticipating desmoids, osteomas, and upper GI polyps from APC variants is unreliable, impacting surgical planning. Kinzler and Vogelstein (1996) highlighted variable expressivity in hereditary syndromes. Phenotypic heterogeneity hinders risk stratification.
Essential Papers
Genetic Alterations during Colorectal-Tumor Development
Bert Vogelstein, Eric R. Fearon, Stanley R. Hamilton et al. · 1988 · New England Journal of Medicine · 6.7K citations
Because most colorectal carcinomas appear to arise from adenomas, studies of different stages of colorectal neoplasia may shed light on the genetic alterations involved in tumor progression. We loo...
Lessons from Hereditary Colorectal Cancer
K. W. Kinzler, Bert Vogelstein · 1996 · Cell · 4.9K citations
Identification of c- <i>MYC</i> as a Target of the APC Pathway
Tong‐Chuan He, Andrew B. Sparks, Carlo Rago et al. · 1998 · Science · 4.5K citations
The adenomatous polyposis coli gene ( APC ) is a tumor suppressor gene that is inactivated in most colorectal cancers. Mutations of APC cause aberrant accumulation of β-catenin, which then binds T ...
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Patrice J. Morin, Andrew B. Sparks, Vladimír Kořínek et al. · 1997 · Science · 3.9K citations
Inactivation of the adenomatous polyposis coli ( APC ) tumor suppressor gene initiates colorectal neoplasia. One of the biochemical activities associated with the APC protein is down-regulation of ...
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · 2017 · Genome Medicine · 3.6K citations
Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability
Asad Umar, C. Richard Boland, Jonathan P. Terdiman et al. · 2004 · JNCI Journal of the National Cancer Institute · 3.2K citations
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a common autosomal dominant syndrome characterized by early age at onset, neoplastic lesions, and microsatellite ...
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Gideon Steinbach, Patrick M. Lynch, Robin Phillips et al. · 2000 · New England Journal of Medicine · 2.5K citations
In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colore...
Reading Guide
Foundational Papers
Start with Vogelstein et al. (1988; 6722 citations) for adenoma-carcinoma sequence, then Kinzler et al. (1991; 2352 citations) for APC discovery, and Kinzler and Vogelstein (1996; 4907 citations) for hereditary cancer lessons.
Recent Advances
Study Steinbach et al. (2000; 2514 citations) for celecoxib trial in FAP; He et al. (1998; 4525 citations) and Morin et al. (1997; 3888 citations) for APC-β-catenin-myc signaling.
Core Methods
Core techniques: APC mutation screening (Kinzler et al., 1991), β-catenin stabilization assays (Morin et al., 1997), polyp counting in chemoprevention RCTs (Steinbach et al., 2000), and Wnt pathway transcription analysis (He et al., 1998).
How PapersFlow Helps You Research Familial Adenomatous Polyposis
Discover & Search
Research Agent uses searchPapers('Familial Adenomatous Polyposis APC mutations') to retrieve 250M+ OpenAlex papers, then citationGraph on Vogelstein et al. (1988; 6722 citations) reveals downstream APC pathway works like Morin et al. (1997). findSimilarPapers expands to β-catenin studies, while exaSearch uncovers recent chemoprevention trials citing Steinbach et al. (2000).
Analyze & Verify
Analysis Agent applies readPaperContent to Steinbach et al. (2000) for celecoxib trial data extraction, then verifyResponse (CoVe) cross-checks claims against Vogelstein et al. (1988). runPythonAnalysis processes polyp reduction stats (28% with 400mg celecoxib) via pandas for meta-analysis visualization. GRADE grading scores evidence as high for short-term efficacy.
Synthesize & Write
Synthesis Agent detects gaps in long-term chemoprevention data post-Steinbach et al. (2000), flags APC variant contradictions across Kinzler et al. (1991) and He et al. (1998). Writing Agent uses latexEditText for genotype-phenotype tables, latexSyncCitations for 10+ FAP papers, latexCompile for review drafts, and exportMermaid for Wnt signaling diagrams.
Use Cases
"Analyze polyp reduction data from FAP chemoprevention trials and plot effect sizes"
Research Agent → searchPapers('FAP celecoxib trial') → Analysis Agent → readPaperContent(Steinbach 2000) → runPythonAnalysis(pandas plot forest plot of 28% reduction vs placebo) → matplotlib visualization of trial outcomes.
"Write LaTeX review section on APC-β-catenin signaling in FAP with citations"
Synthesis Agent → gap detection in APC pathway → Writing Agent → latexEditText('Wnt pathway overview') → latexSyncCitations(Vogelstein 1988, Morin 1997, He 1998) → latexCompile → PDF with diagram via exportMermaid.
"Find code for APC mutation analysis from colorectal cancer papers"
Research Agent → searchPapers('APC mutation FAP analysis code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for variant burden calculation shared via exportCsv.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ FAP papers: searchPapers → citationGraph(Vogelstein 1988) → DeepScan 7-steps with GRADE checkpoints on chemoprevention evidence. Theorizer generates hypotheses on desmoid risk from APC 3' mutations using Kinzler et al. (1991) + recent exaSearch. DeepScan verifies genotype-phenotype claims across datasets with CoVe.
Frequently Asked Questions
What defines Familial Adenomatous Polyposis?
FAP is caused by germline APC mutations leading to >100 colorectal adenomas by age 20, with 100% cancer risk without colectomy (Vogelstein et al., 1988).
What are key methods in FAP research?
Methods include APC sequencing for variants (Kinzler et al., 1991), β-catenin-Tcf assays (Morin et al., 1997), and randomized trials for chemoprevention like celecoxib (Steinbach et al., 2000).
What are foundational FAP papers?
Vogelstein et al. (1988; 6722 citations) mapped colorectal tumor genetics; Kinzler et al. (1991; 2352 citations) identified APC locus; Kinzler and Vogelstein (1996; 4907 citations) reviewed hereditary mechanisms.
What are open problems in FAP?
Challenges include precise genotype-phenotype prediction, long-term chemoprevention beyond celecoxib (Steinbach et al., 2000), and managing extracolonic features like desmoids.
Research Genetic factors in colorectal cancer with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Familial Adenomatous Polyposis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers